News | May 08, 2025
Suven Pharmaceuticals is now Cohance Lifesciences
The change of name has been carried on pursuant to the Scheme of Amalgamation
The change of name has been carried on pursuant to the Scheme of Amalgamation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
The company will address these observations within the stipulated timeline
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
New Board of Directors and management team at Suven Pharma also appointed
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
Subscribe To Our Newsletter & Stay Updated
